A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo-Controlled Study of LY3074828 in Subjects With Active Crohn's Disease (SERENITY)
Phase of Trial: Phase II
Latest Information Update: 07 Oct 2017
At a glance
- Drugs Mirikizumab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms SERENITY
- Sponsors Eli Lilly
- 07 Feb 2017 Status changed from not yet recruiting to recruiting.
- 08 Nov 2016 Planned End Date changed from 1 Jun 2020 to 1 Apr 2021.
- 08 Nov 2016 Planned primary completion date changed from 1 Feb 2019 to 1 Mar 2019.